Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LT-3001
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lumosa Therapeutics and CHI Memorial Announce New Study for Acute Stroke
Details : LT3001 is a tissue plasminogen activator, which is being evaluated in phase 2 clinical trials for the treatment of acute ischemic stroke.
Product Name : LT-3001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 02, 2024
Lead Product(s) : LT-3001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nalbuphine Sebacate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : LT1001 is the world's first week-long extended-release analgesic injection. The approval from Singapore has significance in accelerating the introduction of LT1001 in Southeast Asia.
Product Name : LT1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2020
Lead Product(s) : Nalbuphine Sebacate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable